UroGen Pharma Ltd. (URGN)

UroGen Pharma's stock has been influenced by several events in the past six months. Top-line results from the Phase 3 UTOPIA trial for UGN-103 were reported in November 2025. The Journal of Urology published the ENVISION trial results for ZUSDURI in late March 2026. BlackRock disclosed a new 5.2% passive stake in the company on March 31, 2026. UroGen launched its 'LG-UTUC Luminaries' initiative in April 2026. Jefferies Financial Group upgraded UroGen Pharma's shares to a "strong-buy" rating in April 2026. Oppenheimer raised its price target on the stock in May 2026. UroGen Pharma reported its first-quarter 2026 financial results on May 6, 2026.

UroGen Pharma's products do not appear to exhibit significant demand seasonality, with a stable and predictable demand profile for Jelmyto.

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, leveraging its RTGel™ technology to enhance drug delivery. Its major products include Jelmyto, the first FDA-approved non-surgical therapy for low-grade upper tract urothelial cancer, and Zusduri, approved for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company has a pipeline of investigational therapies, including UGN-102, UGN-103, UGN-104, UGN-201, UGN-301 and UGN-501.

UroGen Pharma Ltd. is headquartered in Princeton, New Jersey, with R&D operations in Israel. Its revenue primarily comes from sales of Jelmyto and Zusduri in the United States, with strategic goals to expand internationally through partnerships.

UroGen Pharma's brand reputation appears positive, driven by favorable clinical trial results and strategic initiatives, including the publication of Phase 3 ENVISION trial data for ZUSDURI and the launch of the 'LG-UTUC Luminaries' initiative. Analyst upgrades and positive earnings reports further bolster investor confidence.

UroGen Pharma Ltd. has significant institutional ownership, with 177 institutional owners and shareholders holding 90.43% of the company. Major institutional owners include Rtw Investments, Lp, Paradigm Biocapital Advisors LP and BlackRock, Inc. Insider ownership stands at 2.28%.